Trends in Prescribing Antibiotic Therapy for Hospitalized Patients with Community-Acquired Pneumonia in Vietnam

Background: Community-acquired pneumonia (CAP) is a serious and common infectious disease with a high rate of morbidity and mortality among adults. Appropriate antibiotic treatment is therefore vital for reducing the disease incidence. Objective: This study aimed at determining the trends in antibiotic use in hospitalized patients with CAP. Methods: A retrospective study involving 479 medical records of hospitalized adults with CAP was undertaken at Tien Giang Central General Hospital in southern Vietnam during 2018–2019. Collected data included patient socio-demographic characteristics and administered antibiotic therapy. Results: Of the 479 CAP cases, 53.8% were female and more than half were aged 65 and above (average age 66.4±18.3 years). Cardiovascular diseases, gastrointestinal disorders, and pulmonary diseases were the most common morbidity of patients with CAP. Overall, 43% of the patients had used antibiotics before hospital admission. In the initial treatment, the most frequent single prescribed antibiotics were amoxicillin/clavulanic acid, ceftriaxone, and levofloxacin. Double combinations of the antibiotics in the initial treatment were used in 75.8% of the cases. Overall, 78.6% of the patients had good responses to the first-choice antibiotics. A negative association was noted between the pneumonia severity and antibiotic effectiveness (P<0.05). Conclusions: Although the initial treatment was successful in the majority of hospitalized patients with CAP, the severity of pneumonia still required attention from healthcare professionals to improve the effectiveness of the treatment.

1. Prina E, Ranzani OT, Torres A. Community-acquired pneumonia. The Lancet. 2015 Sep 12;386(9998):1097-108.
2. Kalil AC, Metersky ML, Klompas M, Muscedere J, Sweeney DA, Palmer LB, Napolitano LM, O'Grady NP, Bartlett JG, Carratalà J, El Solh AA. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clinical Infectious Diseases. 2016 Sep 1;63(5):e61-111.
3. Broulette J, Yu H, Pyenson B, Iwasaki K, Sato R. The incidence rate and economic burden of community-acquired pneumonia in a working-age population. American health & drug benefits. 2013 Sep;6(8):494–50
4. Torres A, Peetermans WE, Viegi G, Blasi F. Risk factors for community-acquired pneumonia in adults in Europe: a literature review. Thorax. 2013 Nov 1;68(11):1057-65.
5. López‐Alcalde J, Rodriguez‐Barrientos R, Redondo‐Sánchez J, Muñoz‐Gutiérrez J, García JM, Rodríguez‐Fernández C, Heras‐Mosteiro J, Casanova‐Colominas J, Azcoaga‐Lorenzo A, Santiago VH, Gómez‐García M. Short‐course versus long‐course therapy of the same antibiotic for community‐acquired pneumonia in adolescent and adult outpatients. Cochrane Database of Systematic Reviews. 2018(9); 9:CD009070.
6. Mauldin PD, Salgado CD, Hansen IS, Durup DT, Bosso JA. Attributable hospital cost and length of stay associated with health care-associated infections caused by antibiotic-resistant gram-negative bacteria. Antimicrobial agents and chemotherapy. 2010 Jan 1;54(1):109-15.
7. Sahuquillo‐Arce JM, Menéndez R, Méndez R, Amara‐Elori I, Zalacain R, Capelastegui A, Aspa J, Borderías L, Martín‐Villasclaras JJ, Bello S, Alfageme I. Age‐related risk factors for bacterial aetiology in community‐acquired pneumonia. Respirology. 2016 Nov;21(8):1472-9.
8. World Health Organization, Causes of death 2008: data sources and methods [Online]. Available: https://www.who.int/healthinfo/global_burden_disease/cod_2008_sources_methods.pdf. [Accessed: 9 Jan, 2020].
9. Almirall J, Bolibar I, Vidal J, Sauca G, Coll P, Niklasson B, Bartolome M, Balanzo X. Epidemiology of community-acquired pneumonia in adults: a population-based study. European Respiratory Journal. 2000 Apr 1;15(4):757-63.
10. Simmerman JM, Chittaganpitch M, Levy J, Chantra S, Maloney S, Uyeki T, Areerat P, Thamthitiwat S, Olsen SJ, Fry A, Ungchusak K. Incidence, seasonality and mortality associated with influenza pneumonia in Thailand: 2005–2008. PloS one. 2009;4(11):e7776.
11. Gutiérrez F, Masiá M, Mirete C, Soldán B, Rodríguez JC, Padilla S, Hernández I, Royo G, Martin-Hidalgo A. The influence of age and gender on the population-based incidence of community-acquired pneumonia caused by different microbial pathogens. Journal of infection. 2006 Sep 1;53(3):166-74.
12. Arnold FW, Wiemken TL, Peyrani P, Ramirez JA, Brock GN. Mortality differences among hospitalized patients with community-acquired pneumonia in three world regions: results from the Community-Acquired Pneumonia Organization (CAPO) International Cohort Study. Respiratory medicine. 2013 Jul 1;107(7):1101-11.
13. Drijkoningen JJ, Rohde GG. Pneumococcal infection in adults: burden of disease. Clinical Microbiology and Infection. 2014 May;20:45-51.
14. Song JH, Thamlikitkul V, Hsueh PR. Clinical and economic burden of community-acquired pneumonia amongst adults in the Asia-Pacific region. International journal of antimicrobial agents. 2011 Aug 1;38(2):108-17.
15. Takahashi K, Suzuki M, Anh NH, Huong LT, Son TV, Ai NT, Morimoto K, Kilgore PE, Anh DD, Ariyoshi K, Yoshida LM. The incidence and aetiology of hospitalised community-acquired pneumonia among Vietnamese adults: a prospective surveillance in Central Vietnam. BMC infectious diseases. 2013 Dec 1;13(1):296.
16. Palmer CS, Zhan C, Elixhauser A, Halpern MT, Ranee L, Feagan BG, Marrie TJ. Economic assessment of the community-acquired pneumonia intervention trial employing levofloxacin. Clinical therapeutics. 2000 Feb 1;22(2):250-64.
17. Carriere KC, Jin Y, Marrie TJ, Predy G, Johnson DH. Outcomes and costs among seniors requiring hospitalization for community‐acquired pneumonia in Alberta. Journal of the American Geriatrics Society. 2004 Jan;52(1):31-8.
18. Tumanan-Mendoza BA, Mendoza VL, Punzalan FE, Reganit PF, Bacolcol SA. Economic burden of community-acquired pneumonia among adults in the Philippines: its equity and policy implications in the case rate payments of the Philippine Health Insurance Corporation. Value in health regional issues. 2015 May 1;6:118-25.
19. Vo TQ. Socioeconomic Burden of Community-acquired Pneumonia Associated Hospitalizations among Vietnamese Patients: A Prospective, Incidence-based Study. Asian Journal of Pharmaceutics (AJP): Free full text articles from Asian J Pharm. 2018 Aug 10;12(01):S38–S47.
20. World Health Organization, ICD-10 Version 2016, [Online]. Available: https://icd.who.int/browse10/2016/en. [Accessed: 10 Jan, 2020].
21. Kolditz M, Tesch F, Mocke L, Höffken G, Ewig S, Schmitt J. Burden and risk factors of ambulatory or hospitalized CAP: a population based cohort study. Respiratory medicine. 2016 Dec 1;121:32-8.
22. Azmi S, Aljunid SM, Maimaiti N, Ali AA, Nur AM, De Rosas-Valera M, Encluna J, Mohamed R, Wibowo B, Komaryani K, Roberts C. Assessing the burden of pneumonia using administrative data from Malaysia, Indonesia, and the Philippines. International Journal of Infectious Diseases. 2016 Aug 1;49:87-93.
23. British Thoracic Society Community-acquired Pneumonia in Adults Guideline Group. Guidelines for the management of Community-acquired pneumonia in adults: update 2009. BMJ Thorax. 2009; 64:iii1-iii55.
24. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, Dowell SF, File Jr TM, Musher DM, Niederman MS, Torres A. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clinical infectious diseases. 2007 Mar 1;44(Supplement_2):S27-72.
25. Niederman MS, Mandell LA, Anzueto A, Bass JB, Broughton WA, Campbell GD, Dean N, File T, Fine MJ, Gross PA, Martinez F. Guidelines for the management of adults with community-acquired pneumonia: diagnosis, assessment of severity, antimicrobial therapy, and prevention. American journal of respiratory and critical care medicine. 2001 Jun 1;163(7):1730-54.
26. National Institute for Health and Care Excellence, Pneumoniae in adults: diagnosis and management. Nice.org.uk/guidance/cg191, [Online]. Available: [Accessed: 10 Jan, 2020].
27. Falk G, Fahey T. C-reactive protein and community-acquired pneumonia in ambulatory care: systematic review of diagnostic accuracy studies. Family practice. 2009 Feb 1;26(1):10-21.
28. Waterer GW, Rello J, Wunderink RG. Management of community-acquired pneumonia in adults. American journal of respiratory and critical care medicine. 2011 Jan 15;183(2):157-64.
29. Johansson N, Kalin M, Tiveljung-Lindell A, Giske CG, Hedlund J. Etiology of community-acquired pneumonia: increased microbiological yield with new diagnostic methods. Clinical Infectious Diseases. 2010 Jan 15;50(2):202-9.
30. Gupta D, Agarwal R, Aggarwal AN, Singh N, Mishra N, Khilnani GC, Samaria JK, Gaur SN, Jindal SK, Pneumonia Guidelines Working Group. Guidelines for diagnosis and management of community-and hospital-acquired pneumonia in adults: Joint ICS/NCCP (I) recommendations. Lung India: Official Organ of Indian Chest Society. 2012 Jul;29(Suppl 2):S27.
31. Lim WS, Baudouin SV, George RC, Hill AT, Jamieson C, Le Jeune I, Macfarlane JT, Read RC, Roberts HJ, Levy ML, Wani M. BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax. 2009 Oct 1;64(Suppl 3):iii1-55.
32. Johns Hopkins Hospital. Antimicrobial Stewardship Program. Antibiotic Guidelines 2015-2016: Treatment Recommendations for Adult Inpatients. Johns Hopkins Hospital Antimicrobial Stewardship Program; 2015.
33. Johns Hopkins Medicine. Antibiotics Guidelines 2015-2016, Johns Hopkins Hospital, Baltimore 2016: pp 83-90.
34. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, Dowell SF, File Jr TM, Musher DM, Niederman MS, Torres A. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clinical infectious diseases. 2007 Mar 1;44(Supplement_2):S27-72.
35. Song JH, Oh WS, Kang CI, Chung DR, Peck KR, Ko KS, Yeom JS, Kim CK, Kim SW, Chang HH, Kim YS. Epidemiology and clinical outcomes of community-acquired pneumonia in adult patients in Asian countries: a prospective study by the Asian network for surveillance of resistant pathogens. International journal of antimicrobial agents. 2008 Feb 1;31(2):107-14.
36. Vardakas KZ, Trigkidis KK, Falagas ME. Fluoroquinolones or macrolides in combination with β-lactams in adult patients hospitalized with community acquired pneumonia: a systematic review and meta-analysis. Clinical Microbiology and Infection. 2017 Apr 1;23(4):234-41.
37. Skalsky K, Yahav D, Lador A, Eliakim-Raz N, Leibovici L, Paul M. Macrolides vs. quinolones for community-acquired pneumonia: meta-analysis of randomized controlled trials. Clinical Microbiology and Infection. 2013 Apr 1;19(4):370-8.